Metagenomi Therapeutics, Inc. cotiza a 1.02 USD y tiene una capitalización bursátil de $39M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collabo…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.73 | $-0.61 | $-0.60 | $-0.55 |
| Estimado | $-0.52 | $-0.55 | $-0.58 | $-0.53 |
| Sorpresa | -40.4% | -10.9% | -3.4% | -3.8% |
| Métrica | MGX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -380.9% | -38.6% | -342.2% |
| Net Margin | -348.5% | -33.6% | -315.0% |
| FCF Margin | -354.9% | -13.9% | -341.0% |
| ROE | -55.4% | -40.4% | -15.0% |
| ROA | -39.7% | -32.0% | -7.7% |
| Current Ratio | 7.22 | 2.84 | +4.38 |
| Debt / Equity | — | 0.28 | — |